Total Payments
$27,083
2024 Payments
$3,383
Companies
28
Transactions
199
Medicare Patients
626
Medicare Billing
$144,506
Payment Breakdown by Category
Research$19,460 (71.9%)
Other$4,160 (15.4%)
Food & Beverage$3,463 (12.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19,460 | 9 | 71.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,160 | 3 | 15.4% |
| Food and Beverage | $3,463 | 187 | 12.8% |
Payments by Type
Research
$19,460
9 transactions
General
$7,623
190 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $12,264 | 8 | $0 (2024) |
| Allergan, Inc. | $11,928 | 45 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $445.34 | 28 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $362.38 | 15 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $290.33 | 15 | $0 (2021) |
| Supernus Pharmaceuticals, Inc. | $241.55 | 12 | $0 (2023) |
| Neuronetics, Inc. | $182.84 | 4 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $175.55 | 11 | $0 (2021) |
| AbbVie Inc. | $142.31 | 7 | $0 (2021) |
| Alkermes, Inc. | $140.14 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,383 | 8 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($3,096) |
| 2023 | $72.30 | 3 | Janssen Pharmaceuticals, Inc ($29.27) |
| 2022 | $72.66 | 3 | Janssen Pharmaceuticals, Inc ($26.34) |
| 2021 | $761.99 | 39 | Supernus Pharmaceuticals, Inc. ($227.25) |
| 2020 | $2,837 | 28 | Allergan, Inc. ($2,426) |
| 2019 | $11,687 | 61 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($9,169) |
| 2018 | $401.76 | 24 | Otsuka America Pharmaceutical, Inc. ($110.52) |
| 2017 | $7,866 | 33 | Allergan Inc. ($7,396) |
All Payment Transactions
199 individual payment records from CMS Open Payments — Page 8 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/04/2017 | Braeburn Pharmaceuticals, Inc. | Probuphine (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Opioid addiction | ||||||
| 09/19/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.30 | General |
| Category: NEUROSCIENCE | ||||||
| 08/28/2017 | Shire North American Group Inc | MYDAYIS (Drug) | Food and Beverage | In-kind items and services | $22.38 | General |
| Category: NEUROSCIENCE | ||||||
| 08/24/2017 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 08/16/2017 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 08/14/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: PSYCHIATRY | ||||||
| 07/28/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.96 | General |
| Category: NEUROSCIENCE | ||||||
| 07/12/2017 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 06/14/2017 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: CNS | ||||||
| 06/07/2017 | Braeburn Pharmaceuticals, Inc. | Probuphine (Drug) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: Opioid addiction | ||||||
| 06/07/2017 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 06/01/2017 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 05/12/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: PSYCHIATRY | ||||||
| 05/12/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.10 | General |
| Category: NEUROSCIENCE | ||||||
| 05/04/2017 | Shire North American Group Inc | VYVANSE (Drug) | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: NEUROSCIENCE | ||||||
| 04/14/2017 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 03/30/2017 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $13.04 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 03/23/2017 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 03/21/2017 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: CNS | ||||||
| 03/17/2017 | Braeburn Pharmaceuticals, Inc. | Probuphine (Drug) | Food and Beverage | In-kind items and services | $12.47 | General |
| Category: Opioid addiction | ||||||
| 02/17/2017 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 02/01/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $70.07 | General |
| Category: NEUROSCIENCE | ||||||
| 01/26/2017 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $10.92 | General |
| Category: CNS | ||||||
| 01/11/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $95.79 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLEDTRIAL TO EVALUATE THE EFFICACY OF BREXPIPRAZOLE MONOTHERAPY FOR THE TREATMENT IN ADOLESCENTS 13-17 YEARS OLD WITH SCHIZOPHRENIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $7,979 | 1 |
| A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $7,196 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLEDTRIAL TO EVALUATE THE EFFICACY OF BREXPIPRAZOLE MONOTHERAPY FOR THE TREATMENT IN ADOLESCENTS (13-17 YEARS OLD) WITH SCHIZOPHRENIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,096 | 1 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,190 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 82 | 237 | $71,600 | $17,340 |
| 2022 | 4 | 120 | 303 | $155,310 | $24,960 |
| 2021 | 5 | 186 | 439 | $255,740 | $46,128 |
| 2020 | 5 | 238 | 638 | $272,364 | $56,078 |
Total Patients
626
Total Services
1,617
Medicare Billing
$144,506
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 35 | 190 | $57,000 | $13,537 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $10,750 | $2,587 | 24.1% |
| 96130 | Evaluation of psychological test, first hour | Office | 2023 | 11 | 11 | $2,750 | $968.03 | 35.2% |
| 96136 | Administration of psychological or neuropsychological test, first 30 minutes | Office | 2023 | 11 | 11 | $1,100 | $247.63 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 243 | $73,030 | $18,858 | 25.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 19 | 22 | $70,560 | $3,261 | 4.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $10,320 | $2,568 | 24.9% |
| 96136 | Administration of psychological or neuropsychological test, first 30 minutes | Office | 2022 | 14 | 14 | $1,400 | $273.10 | 19.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 68 | 315 | $94,760 | $31,351 | 33.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 51 | 51 | $21,930 | $6,729 | 30.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2021 | 33 | 38 | $130,545 | $5,459 | 4.2% |
| 96130 | Psychological testing evaluation by qualified health care professional, first 60 minutes | Office | 2021 | 21 | 21 | $6,405 | $2,058 | 32.1% |
| 96136 | Psychological or neuropsychological test administration and scoring by qualified health care professional, first 30 minutes | Office | 2021 | 13 | 14 | $2,100 | $530.18 | 25.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 93 | 485 | $197,861 | $38,620 | 19.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 64 | 64 | $41,489 | $10,643 | 25.7% |
| 96130 | Psychological testing evaluation by qualified health care professional, first 60 minutes | Office | 2020 | 38 | 38 | $11,260 | $3,732 | 33.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 18 | 18 | $12,102 | $1,820 | 15.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 25 | 33 | $9,653 | $1,263 | 13.1% |
About Dr. Akindele Kolade, M.D
Dr. Akindele Kolade, M.D is a Psychiatry healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922051846.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Akindele Kolade, M.D has received a total of $27,083 in payments from pharmaceutical and medical device companies, with $3,383 received in 2024. These payments were reported across 199 transactions from 28 companies. The most common payment nature is "" ($19,460).
As a Medicare-enrolled provider, Kolade has provided services to 626 Medicare beneficiaries, totaling 1,617 services with total Medicare billing of $144,506. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry, Child & Adolescent Psychiatry
- Location Las Vegas, NV
- Active Since 05/19/2006
- Last Updated 11/11/2025
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1922051846
Products in Payments
- FETZIMA (Drug) $7,196
- VRAYLAR (Drug) $4,874
- REXULTI (Drug) $3,262
- SPRAVATO (Drug) $362.38
- NUEDEXTA (Drug) $290.33
- QELBREE (Drug) $241.55
- ABILIFY MAINTENA (Drug) $234.67
- LATUDA (Drug) $175.55
- NEUROSTAR TMS THERAPY SYSTEM (Device) $150.76
- Dayvigo (Drug) $100.96
- SUBLOCADE (Drug) $96.46
- VYVANSE (Drug) $83.24
- BrainsWay Deep TMS (Device) $78.68
- ARISTADA (Drug) $72.79
- Probuphine (Drug) $71.90
- ABILIFY MYCITE (Drug) $63.05
- AUSTEDO (Drug) $57.01
- Lucemyra (Drug) $53.23
- CAPLYTA (Drug) $48.22
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $47.65
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Las Vegas
Jelena Kunovac, M.d, M.D
Psychiatry — Payments: $1.4M
Psychiatry $1.4M
Dr. John Anooshian, Md, MD
Psychiatry — Payments: $861,533
Psychiatry $861,533
Sam Zand, D.o, D.O
Psychiatry — Payments: $350,533
Psychiatry $350,533
Dr. Mustafa Rawaf, Do, DO
Psychiatry — Payments: $150,352
Psychiatry $150,352
Aaron Ritter, Md, MD
Psychiatry — Payments: $122,008
Psychiatry $122,008
Dr. Faisal Suba, M.d, M.D
Psychiatry — Payments: $41,047
Psychiatry $41,047